Cedric Gougler is an accomplished leader in the field of strategic and operational development, renowned for his ability to drive growth and deliver exceptional results, particularly in the aesthetic medicine market. With over two decades of experience, Cedric has consistently demonstrated a visionary approach and unwavering commitment to excellence, making him a pivotal force in advancing business success.

As the founder of West Link Holding, Cedric has shaped global strategies for aesthetic medicine, advising companies worldwide on navigating complex markets. He is also a partner and advisor at Ondoegone Laboratory, where he provides expert guidance in strategic distribution and business organization. His extensive expertise extends to private equity, having worked with Archimed, where he contributed to key acquisitions, conducted international commercial audits, and managed transitions for companies in the consumer health sector.

Earlier in his career, Cedric founded SBS-Med and its flagship brand Dermafill Manificare, leading the strategic and operational growth of the company for 12 years, including the creation of a branded range of hyaluronic acid fillers and mesotherapy products. His international experience also includes pivotal roles at Laboratoires Filorga (now FILLMED), where he built and restructured the company’s global distribution network, and at Academié Scientifique de Beauté, Claranet, and GS America, where he honed his expertise in marketing and business development.

Cedric’s vast experience and forward-thinking approach continue to inspire growth and innovation across the businesses he advises, making him an invaluable asset to any organization.

Jan Willem de Cler is an accomplished executive with a proven track record in leading transformation and driving growth across global organizations. With extensive experience in both the MedTech and industrial sectors, he served as Board Member and CHRO/COO/CSO at Carl Zeiss Meditec AG, a €2 billion revenue company with 6,500 employees worldwide. In this role, he spearheaded cultural transformations, streamlined global supply chains, expanded service operations and led innovation through strategic mergers and acquisitions.

As Strategic Business Unit (SBU) Head, Jan Willem built a €500 million Ophthalmic Surgery Solutions business by instilling a customer-centric approach, accelerating growth, and scaling the organization internationally. His leadership was instrumental in executing successful turnarounds and restructuring strategies across various countries, always focusing on teamwork, customer satisfaction, and profitability.

Currently, Jan Willem holds senior advisory roles with prominent private equity firms and serves as Chairman of the Board at Implandata Ophthalmic Products GmbH and Vice Chairman of the Supervisory Board at Ottobock SE & Co. KGaA. His earlier career spans leadership roles at General Electric in sales, marketing, business development and corporate audit across multiple industries, including healthcare and technology.

Jan Willem’s diverse experience and strategic insights continue to shape the future of the organizations he advises, making him an invaluable partner in achieving sustainable growth and innovation.